Why this diabetes drug works better than others
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This medicine helps the pancreas make insulin better and makes the body more sensitive to insulin — even when you don’t lose much weight.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 572 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This medicine helps the pancreas make insulin better and makes the body more sensitive to insulin — even when you don’t lose much weight.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 572 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA
Related Content
Claims (6)
GLP-1 receptor agonists trigger changes in the body that occur even when weight loss is accounted for, suggesting these drugs have effects beyond reducing body weight.
In people with type 2 diabetes, tirzepatide lowers fasting glucagon levels more than dulaglutide, which may help reduce excessive glucose release from the liver and improve blood sugar control.
In people with type 2 diabetes, the medication tirzepatide at 10 mg and 15 mg improves how the body responds to insulin more than can be explained by weight loss alone, suggesting other biological mechanisms are involved.
In people with type 2 diabetes, a medication called tirzepatide at doses of 5 mg or higher raises levels of certain blood proteins—adiponectin, IGFBP-1, and IGFBP-2—more than another medication called dulaglutide. These proteins are linked to better insulin sensitivity.
In people with type 2 diabetes, a weekly injection of tirzepatide at 10 mg or 15 mg is associated with better function of insulin-producing cells in the pancreas, shown by specific biomarker changes, compared to other treatments like dulaglutide or no active treatment.